Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2020

01-08-2020 | Breast Cancer | Epidemiology

Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population

Authors: Nupur Rani Howlader, Md. Mostafizur Rahman, Md. Amir Hossain, Razia Sultana, Syed Mozammel Hossain, Md. Abdul Mazid, Md. Mustafizur Rahman

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Abstract

Background

Genetic polymorphisms in DNA repair genes, XRCC1 (Arg399Gln) and XRCC3 (Thr241Met), may affect their DNA repair capacity leading to individual variation in breast cancer susceptibility among Bangladeshi females.

Methods

The case–control study comprised 121 breast cancer patients and 133 healthy controls. Genomic DNA isolated from peripheral blood was genotyped for target SNPs using PCR-RFLP method.

Results

For XRCC1, heterozygous Arg/Gln and homozygous Gln/Gln genotypes showed 1.78-fold (95% CI 1.0084 to 3.1442, p = 0.0467) and 2.41-fold (95% CI 1.0354 to 5.5914, p = 0.0413) increased risk of breast cancer, respectively, when compared with Arg/Arg genotype. The presence of any XRCC1 Gln showed association with 1.93-fold increased risk. The variant Gln allele was associated with increased risk of breast cancer (95% CI 1.1885 to 2.6805, p = 0.0052). For XRCC3, Thr/Met heterozygous and combined Thr/Met + Met/Met genotypes were associated with 1.85-fold (95% CI 1.0815 to 3.1834, p = 0.0248) and 1.89-fold (95% CI 1.1199 to 3.1908, p = 0.0171) higher risk, respectively, compared to Thr/Thr genotypes. The variant Met allele showed significant association with increased breast cancer susceptibility. Among cases genotype frequencies were significantly different in patients with age 55 or above, and with menopause and diabetes.

Conclusion

XRCC1 (Arg399Gln) and XRCC3 (Thr241Met) polymorphisms may be associated with increased breast cancer risk in Bangladeshi females.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Ervik M, Lam F et al (2018) Global cancer observatory: cancer today. International Agency for Research on Cancer, Lyon
2.
McGuire A, Brown JAL, Malone C et al (2015) Effects of age on the detection and management of breast cancer. Cancers (Basel) 7:908–929
3.
Bray F, Ferlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424PubMed
4.
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J cancer 136:E359–E386PubMed
5.
Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes. Science 291:1284–1289PubMed
6.
Kubota Y, Nash RA, Klungland A et al (1996) Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein. EMBO J 15:6662–6670PubMedPubMedCentral
7.
Tudek B (2007) Base excision repair modulation as a risk factor for human cancers. Mol Asp Med 28:258–275
8.
Shen H, Wang X, Hu Z et al (2004) Polymorphisms of DNA repair gene XRCC3 Thr241Met and risk of gastric cancer in a Chinese population. Cancer Lett 206:51–58PubMed
9.
Figueiredo JC, Knight JA, Briollais L et al (2004) Polymorphisms XRCC1-R399Q and XRCC3-T241M and the risk of breast cancer at the Ontario site of the Breast Cancer Family Registry. Cancer Epidemiol Prev Biomark 13:583–591
10.
Webb PM, Hopper JL, Newman B et al (2005) Double-strand break repair gene polymorphisms and risk of breast or ovarian cancer. Cancer Epidemiol Prev Biomark 14:319–323
11.
Khlifi R, Kallel I, Hammami B et al (2014) DNA repair gene polymorphisms and risk of head and neck cancer in the Tsunisian population. J Oral Pathol Med 43:217–224PubMed
12.
Duell EJ, Millikan RC, Pittman GS et al (2001) Polymorphisms in the DNA repair gene XRCC1 and breast cancer. Cancer Epidemiol Prev Biomark 10:217–222
13.
Han J, Hankinson SE, De Vivo I et al (2003) A prospective study of XRCC1 haplotypes and their interaction with plasma carotenoids on breast cancer risk. Cancer Res 63:8536–8541PubMed
14.
Smith TR, Levine EA, Perrier ND et al (2003) DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Prev Biomark 12:1200–1204
15.
Shen J, Gammon MD, Terry MB et al (2005) Polymorphisms in XRCC1 modify the association between polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, dietary antioxidants, and breast cancer risk. Cancer Epidemiol Prev Biomark 14:336–342
16.
17.
Bu D, Tomlinson G, Lewis CM et al (2006) An intronic polymorphism associated with increased XRCC1 expression, reduced apoptosis and familial breast cancer. Breast Cancer Res Treat 99:257–265PubMed
18.
Thyagarajan B, Anderson KE, Folsom AR et al (2006) No association between XRCC1 and XRCC3 gene polymorphisms and breast cancer risk: Iowa Women’s Health Study. Cancer Detect Prev 30:313–321PubMed
19.
Sangrajrang S, Schmezer P, Burkholder I et al (2007) The XRCC3 Thr241Met polymorphism and breast cancer risk: a case–control study in a Thai population. Biomarkers 12:523–532PubMed
20.
Costa S, Pinto D, Pereira D et al (2007) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103:209–217PubMed
21.
Economopoulos KP, Sergentanis TN (2010) XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 121:439–443PubMed
22.
23.
Daly AK, Monkman SC, Smart J et al (1998) Analysis of cytochrome P450 polymorphisms. Cytochrome P450 protocols. Springer, New York, pp 405–422
24.
Saiki RK, Gelfand DH, Stoffel S et al (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487–491PubMed
25.
Siegel RL, Miller KD, Jemal A (2016) Cancer statistics. CA Cancer J Clin 66:7–30PubMed
26.
Landi S (2009) Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat Res 681:299–307PubMed
27.
Chu D, Kohlmann W, Adler DG (2010) Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP J Pancreas 11:203–212
28.
Lowenfels AB, Maisonneuve P (2003) Environmental factors and risk of pancreatic cancer. Pancreatology 3:1–8PubMed
29.
Wong H, Wilson DM (2005) XRCC1 and DNA polymerase β interaction contributes to cellular alkylating-agent resistance and single-strand break repair. J Cell Biochem 95:794–804PubMed
30.
Liu N, Lamerdin JE, Tebbs RS et al (1998) XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. Mol Cell 1:783–793PubMed
31.
Pierce AJ, Johnson RD, Thompson LH, Jasin M (1999) XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13:2633–2638PubMedPubMedCentral
32.
Smolarz B, Makowska M, Samulak D et al (2014) Single nucleotide polymorphisms (SNPs) of ERCC2, hOGG1, and XRCC1 DNA repair genes and the risk of triple-negative breast cancer in Polish women. Tumor Biol 35:3495–3502
33.
Han J, Haiman C, Niu T et al (2009) Genetic variation in DNA repair pathway genes and premenopausal breast cancer risk. Breast Cancer Res Treat 115:613–622PubMed
34.
Wang L, Wang G, Lu C et al (2012) Contribution of the-160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies. PLoS ONE 7:e40219PubMedPubMedCentral
35.
Jeanes A, Gottardi CJ, Yap AS (2008) Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27:6920PubMedPubMedCentral
36.
Popanda O, Tan X-L, Ambrosone CB et al (2006) Genetic polymorphisms in the DNA double-strand break repair genes XRCC3, XRCC2, and NBS1 are not associated with acute side effects of radiotherapy in breast cancer patients. Cancer Epidemiol Prev Biomark 15:1048–1050
37.
Kuschel B, Auranen A, McBride S et al (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11:1399–1407PubMed
38.
Rao KS, Paul A, Kumar ASA et al (2014) Allele and genotype distributions of DNA repair gene polymorphisms in South Indian healthy population. Biomark Cancer 6:BIC-S19681
39.
Takeshita H, Fujihara J, Yasuda T, Kimura-Kataoka K (2015) Worldwide distribution of four SNPs in X-ray and repair and cross-complementing group 1 (XRCC1). Clin Transl Sci 8:347–350PubMed
40.
Goričar K, Kovač V, Dolžan V (2017) Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma. Sci Rep 7:46537PubMedPubMedCentral
41.
Sterpone S, Mastellone V, Padua L et al (2010) Single-nucleotide polymorphisms in BER and HRR genes, XRCC1 haplotypes and breast cancer risk in Caucasian women. J Cancer Res Clin Oncol 136:631–636PubMed
42.
Chacko P, Rajan B, Joseph T et al (2005) Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat 89:15–21PubMed
43.
Luo H, Li Z, Qing Y et al (2014) Single nucleotide polymorphisms of DNA base-excision repair genes (APE1, OGG1 and XRCC1) associated with breast cancer risk in a Chinese population. Asian Pac J Cancer Prev 15:1133–1140PubMed
44.
Ramadan RA, Desouky LM, Elnaggar MA et al (2014) Association of DNA repair genes XRCC1 (Arg399Gln),(Arg194Trp) and XRCC3 (Thr241Met) polymorphisms with the risk of breast cancer: a case–control study in Egypt. Genet Test Mol Biomark 18:754–760
45.
Shadrina AS, Ermolenko NA, Boyarskikh UA et al (2016) Polymorphisms in DNA repair genes and breast cancer risk in Russian population: a case–control study. Clin Exp Med 16:21–28PubMed
46.
Syamala VS, Syamala V, Sreedharan H et al (2009) Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report. Pathol Oncol Res 15:389PubMed
47.
48.
Romanowicz H, Smolarz B, Baszczyński J et al (2010) Genetics polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the Polish population. Pol J Pathol 61:206–212PubMed
49.
Macías-Gómez NM, Peralta-Leal V, Meza-Espinoza JP et al (2015) Polymorphisms of the XRCC1 gene and breast cancer risk in the Mexican population. Fam Cancer 14:349–354PubMed
50.
Romanowicz H, Pyziak Ł, Jabłoński F et al (2017) Analysis of DNA repair genes polymorphisms in breast cancer. Pathol Oncol Res 23:117–123PubMed
51.
Roberts MR, Shields PG, Ambrosone CB et al (2011) Single-nucleotide polymorphisms in DNA repair genes and association with breast cancer risk in the web study. Carcinogenesis 32:1223–1230PubMedPubMedCentral
52.
Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58:604–608PubMed
53.
Lunn RM, Langlois RG, Hsieh LL et al (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin a variant frequency. Cancer Res 59:2557–2561PubMed
54.
Duell EJ, Wiencke JK, Cheng T-J et al (2000) Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965–971PubMed
55.
Al Mutairi FM, Alanazi M, Shalaby M et al (2013) Association of XRCC1 gene polymorphisms with breast cancer susceptibility in Saudi patients. Asian Pac J Cancer Prev 14:3809–3813PubMed
56.
Hussien Y, Gharib A, Karam R, Elsawy W (2011) Impact of DNA repair gene polymorphisms (XPD and XRCC1) on the risk of breast cancer in Egyptian female patients. Bull Egypt Soc Physiol Sci 31:91–106
57.
Metsola K, Kataja V, Sillanpää P et al (2005) XRCC1 and XPD genetic polymorphisms, smoking and breast cancer risk in a Finnish case-control study. Breast Cancer Res 7:R987PubMedPubMedCentral
58.
Zipprich J, Terry MB, Brandt-Rauf P et al (2010) XRCC1 polymorphisms and breast cancer risk from the New York Site of the breast cancer family Registry: a family-based case-control study. J Carcinog 9:4PubMedPubMedCentral
59.
Kim S-U, Park SK, Yoo K-Y et al (2002) XRCC1 genetic polymorphism and breast cancer risk. Pharmacogenet Genom 12:335–338
60.
Moghaddam AS, Nazarzadeh M, Moghaddam HS et al (2016) XRCC1 gene polymorphisms and breast cancer risk: a systematic review and meta-analysis study. Asian Pac J Cancer Prev 17:323–335
61.
Wu K, Su D, Lin K et al (2011) XRCC1 Arg399Gln gene polymorphism and breast cancer risk: a meta-analysis based on case-control studies. Asian Pac J Cancer Prev 12:2237–2243PubMed
62.
Saadat M (2010) Haplotype analysis of XRCC1 (at codons 194 and 399) and susceptibility to breast cancer, a meta-analysis of the literatures. Breast Cancer Res Treat 124:785–791PubMed
63.
Zdzienicka MZ (1999) Mammalian X-ray-sensitive mutants which are defective in non-homologous (illegitimate) DNA double-strand break repair. Biochimie 81:107–116PubMed
64.
Thacker J, Zdzienicka MZ (2004) The XRCC genes: expanding roles in DNA double-strand break repair. DNA Repair (Amst) 3:1081–1090
65.
Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ (2000) XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res Repair 459:89–97
66.
Richardson C (2005) RAD51, genomic stability, and tumorigenesis. Cancer Lett 218:127–139PubMed
67.
García-Closas M, Egan KM, Newcomb PA et al (2006) Polymorphisms in DNA double-strand break repair genes and risk of breast cancer: two population-based studies in USA and Poland, and meta-analyses. Hum Genet 119:376PubMed
68.
Bastos HN, Antao MR, Silva SN et al (2009) Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk. Thyroid 19:1067–1075PubMed
69.
Sturgis EM, Zhao C, Zheng R, Wei Q (2005) Radiation response genotype and risk of differentiated thyroid cancer: a case-control analysis. Laryngoscope 115:938–945PubMed
70.
Qureshi Z, Mahjabeen I, Baig RM, Kayani MA (2014) Correlation between selected XRCC2, XRCC3 and RAD51 gene polymorphisms and primary breast cancer in women in Pakistan. Asian Pac J Cancer Prev 15:10225–10229PubMed
71.
Smolarz B, Makowska M, Samulak D et al (2015) Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and triple-negative breast cancer in Polish women. Clin Exp Med 15:151–157PubMed
72.
Krupa R, Synowiec E, Pawlowska E et al (2009) Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer. Exp Mol Pathol 87:32–35PubMed
73.
Sobczuk A, Romanowicz-Makowska H, Fiks T et al (2009) XRCC1 and XRCC3 DNA repair gene polymorphisms in breast cancer women from the Lodz region of Poland. Polish J Pathol 60:76–80
74.
Su C-H, Chang W-S, Hu P-S et al (2015) Contribution of DNA double-strand break repair gene XRCC3 genotypes to triple-negative breast cancer risk. Cancer Genom-Proteom 12:359–367
75.
Loizidou MA, Michael T, Neuhausen SL et al (2008) Genetic polymorphisms in the DNA repair genes XRCC1, XRCC2 and XRCC3 and risk of breast cancer in Cyprus. Breast Cancer Res Treat 112:575–579PubMed
76.
77.
Devi KR, Ahmed J, Narain K et al (2017) DNA repair mechanism gene, XRCC1A (Arg194Trp) but not XRCC3 (Thr241Met) polymorphism increased the risk of breast cancer in premenopausal females: a case–control study in northeastern Region of India. Technol Cancer Res Treat 16:1150–1159PubMedPubMedCentral
78.
Al ZMS, Zavaglia K, Mazanti C et al (2017) Polymorphisms and mutations in GSTP1, RAD51, XRCC1 and XRCC3 genes in breast cancer patients. Int J Biol Markers 32:337–343
79.
Jordan S, Lim L, Vilainerun D et al (2009) Breast cancer in the Thai Cohort Study: an exploratory case-control analysis. The Breast 18:299–303PubMed
Metadata
Title
Genetic polymorphisms in DNA repair genes XRCC1 and 3 are associated with increased risk of breast cancer in Bangladeshi population
Authors
Nupur Rani Howlader
Md. Mostafizur Rahman
Md. Amir Hossain
Razia Sultana
Syed Mozammel Hossain
Md. Abdul Mazid
Md. Mustafizur Rahman
Publication date
01-08-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05738-8

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Clinical trial

Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer

Epidemiology

A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer

Letter to the Editor

Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis

Preclinical study

ETS transcription factor ESE-1/Elf3 is an independent prognostic factor of survival in HR+HER2+ breast cancer patients

Clinical trial

Chronic adverse effects after an axillary lymphadenectomy in breast cancer patients after administering weaker and stronger postoperative analgesia: results of a prospective double-blind randomized study

Preclinical study

The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits